Areas of focus - microbiosensor

MicroBioSensor is addressing a number of unmet market needs for faster infection diagnosis with a range of disposable, point-of-care IVD products.

The following are our key areas of focus.

Kidney Disease

Around 10% of the world’s population has some form of chronic kidney disease, with approximately three million patients requiring either haemodialysis (HD) or peritoneal dialysis (PD).

One of the most frequent complications undermining the success of PD is peritonitis, which is the inflammation of the peritoneum or peritoneal membrane. Contamination during a peritoneal dialysis session is a typical cause. Prevention of peritonitis and prompt and appropriate management is essential for the long-term success of peritoneal dialysis in all patients. One in 20 peritonitis episodes results in the death of the patient.

Samples are sent to central hospital microbiology laboratories for testing, to confirm infection. At best, it takes several hours to obtain a WBC count and confirm infection and it always takes >2 days to obtain antibiotic susceptibility information.

“The diagnostic results usually arrive 48h too late to have a meaningful impact on patient treatment…” Anand Vardhan, Consultant Nephrologist, MRI.

MicroBioSensor is developing products to address this unmet need in peritonitis diagnosis.

Advanced Liver Disease

The global prevalence of liver cirrhosis is estimated at 4.5% to 9.5%, or 50 million adults. 600,000 people in the UK have some form of serious liver disease, and it is the third leading cause of premature mortality. More than £2 billion is spent annually treating liver disease in England alone.

Approximately 50% of patients diagnosed with cirrhosis will go on to develop ascites, with 25% of those developing Spontaneous Bacterial Peritonitis (SBP), a serious complication and cause of death for cirrhosis patients.

For diagnosis, ascitic fluid is sent to the central hospital microbiology laboratory to confirm infection. This typically takes >24-hours to be completed.

MicroBioSensor is developing an in-clinic test that confirms SBP in seconds.